The Parkinson’s Foundation prioritizes the needs and trust of the Parkinson’s community above all else. We believe raising awareness regarding the opportunities to participate in relevant clinical trials is important to accelerate the development of treatments and a cure. The Foundation encourages all people living with Parkinson’s disease to consider participation in a clinical trial. However, the Foundation does not recommend or endorse studies of corporate partners or other external organizations.
The following is a list of current clinical trials conducted by trusted industry partners and supporters of the Parkinson’s Foundation. The information provided below and in the links are for your convenience only and are not offered as an endorsement or recommendation to participate. For a complete list of PD-related trials, please visit the National Institutes of Health website: www.clinicaltrials.gov.
Biogen
The REASON Study is evaluating an investigational drug targeting the LRRK2 gene. Mutations in the LRRK2 gene (which provides instructions for making LRRK2 protein) are known to be associated with PD. Research studies have shown that one of the reasons for PD may be having too much LRRK2 protein in the brain. The study drug is designed to potentially reduce how much LRRK2 is produced by blocking some of the genetic instructions to create this protein. This is a phase 1 study, meaning that the study will be evaluating the investigational drug's safety for the first time in humans.
Read more about the REASON study here.
For more insights on this topic, listen to our podcast episodes “The Golden Year for Testing Disease Modifying Drugs” and “Repurposing Medications to Slow Progression of PD.”
